NASDAQ · SHPH

Shuttle Pharmaceuticals Holdings, Inc.

$2.92 +$0.03 (+1.04%) 1D After hours

Key Metrics

$1.69M
Market cap
P/E · TTM
Revenue · TTM
−$10.82M
Net income
EPS · TTM $-26.92
Dividend yield
Free cash flow
Beta · 1Y 0.51
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 87%.

    Peak close $21.90 on Jan 29; trough close $2.89 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -87%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 14
    The stock moved +40.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 14
  • May 1
    The stock moved -32.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 1

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.69M
Enterprise value
Shares outstanding585.1K
52-wk range$1.26 – $44.40
Avg volume · 20D204.6K
Net cash
Book value / share$8.32
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Shuttle Pharmaceuticals Holdings, Inc.
IPO dateAug 31, 2022
Employees2

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -533.7% · —

Financial Health

Current ratio0.30
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$5.84M

Cash Flow · TTM

Operating CF −$9.37M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings